Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) Short Interest Update

Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) saw a significant increase in short interest in the month of February. As of February 15th, there was short interest totalling 41,500 shares, an increase of 42.6% from the January 31st total of 29,100 shares. Currently, 3.7% of the company’s shares are short sold. Based on an average daily volume of 57,400 shares, the short-interest ratio is presently 0.7 days.

Hedge Funds Weigh In On Cadrenal Therapeutics

An institutional investor recently bought a new position in Cadrenal Therapeutics stock. Geode Capital Management LLC bought a new stake in Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 10,554 shares of the company’s stock, valued at approximately $153,000. Geode Capital Management LLC owned 0.59% of Cadrenal Therapeutics as of its most recent SEC filing. 7.92% of the stock is currently owned by institutional investors and hedge funds.

Cadrenal Therapeutics Stock Up 1.0 %

Shares of NASDAQ:CVKD traded up $0.17 during mid-day trading on Tuesday, reaching $17.57. 55,690 shares of the company’s stock were exchanged, compared to its average volume of 48,134. The firm has a market cap of $31.33 million, a price-to-earnings ratio of -2.63 and a beta of 1.37. The firm’s fifty day simple moving average is $17.94. Cadrenal Therapeutics has a twelve month low of $5.40 and a twelve month high of $22.90.

Analyst Ratings Changes

Separately, HC Wainwright lifted their price target on shares of Cadrenal Therapeutics from $3.00 to $32.00 and gave the stock a “buy” rating in a report on Monday, November 11th.

Cadrenal Therapeutics Company Profile

Cadrenal Therapeutics, Inc operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, atrial fibrillation, and thrombotic anti-phospholipid syndrome.